Zuoquan Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zuoquan Xie has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
- Meiyu Geng
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
18 shared publications Meiyu Geng
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China; University of Chinese Academy of Sciences, Beijing 100049, PR China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, PR China
16 shared publications- Tao Meng
HuaO Therapeutics
15 shared publications - Xiyuan Wang
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
15 shared publications - Biyu Yang
State Key Laboratory of Chemical Biology, Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Shanghai 201203, China
14 shared publications - Deqiang Zhang
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
14 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1-2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Supplementary Table S1. Structure and characterization of MTT1-8. Table S2. the sequence of human TLR7 and TLR8.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1-2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Supplementary Table S1. Structure and characterization of MTT1-8. Table S2. the sequence of human TLR7 and TLR8.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S4 ESI-MS analysis (deconvoluted mass spectra) and DAR calculation. (A) Tras-MTL1. (B) Tras-DXd. (C) Tras-DXd-MTL1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S4 ESI-MS analysis (deconvoluted mass spectra) and DAR calculation. (A) Tras-MTL1. (B) Tras-DXd. (C) Tras-DXd-MTL1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S5. Tumor weight and flow cytometry analysis of tumor infiltrating leukocytes in EMT6-HER2 tumor model. (A) Tumor weight of Fig. 5A. (B-D) Gating strategy for flow cytometry analysis of immune subset in tumor samples. (E-H) EMT6-HER2 tumor were treated with control (0.9%NaCl), trastuzumab (1 mg/kg), Tras-DXd (1 mg/kg), or Tras-DXd-MTL1 (1 mg/kg) for 2 days (n=5), and immune subsets in tumor tissue were analyzed by flow cytometry, and the proportion macrophages (E), CD86+ macrophages (F), CD206+ macrophages (G), and CD3+T cells (H) were shown. The data were shown as mean ± SEM, One-way ANOVA (A, E-G) with Tukey’s correction were used for multiple comparisons. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S5. Tumor weight and flow cytometry analysis of tumor infiltrating leukocytes in EMT6-HER2 tumor model. (A) Tumor weight of Fig. 5A. (B-D) Gating strategy for flow cytometry analysis of immune subset in tumor samples. (E-H) EMT6-HER2 tumor were treated with control (0.9%NaCl), trastuzumab (1 mg/kg), Tras-DXd (1 mg/kg), or Tras-DXd-MTL1 (1 mg/kg) for 2 days (n=5), and immune subsets in tumor tissue were analyzed by flow cytometry, and the proportion macrophages (E), CD86+ macrophages (F), CD206+ macrophages (G), and CD3+T cells (H) were shown. The data were shown as mean ± SEM, One-way ANOVA (A, E-G) with Tukey’s correction were used for multiple comparisons. ns, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S1. Synthetic procedure of drug-linker MTL1 (A) and 1H-NMR spectrum of MTL1 (B).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S1. Synthetic procedure of drug-linker MTL1 (A) and 1H-NMR spectrum of MTL1 (B).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S3. Expression of CD40+DCs in PBMC. PBMC was treated with gradient concentrations of R848 and MTT-6 for 24 h, and the expression level of CD40 in DC cells (CD11b+CD11c+) was measured by flow cytometry, shown as the representative images.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S3. Expression of CD40+DCs in PBMC. PBMC was treated with gradient concentrations of R848 and MTT-6 for 24 h, and the expression level of CD40 in DC cells (CD11b+CD11c+) was measured by flow cytometry, shown as the representative images.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S2. HEK293T-luci cells expressing the NF-κB reporter system were treated with TNF-α (40 ng/ml), MTT-5 (10 µM), R848 (10 µM) and control (0.1%DMSO) for 24 h. The data were shown as mean ± SEM, and one-way ANOVA was used for multiple comparisons. ns, not significant, ****P < 0.0001.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Figure S2. HEK293T-luci cells expressing the NF-κB reporter system were treated with TNF-α (40 ng/ml), MTT-5 (10 µM), R848 (10 µM) and control (0.1%DMSO) for 24 h. The data were shown as mean ± SEM, and one-way ANOVA was used for multiple comparisons. ns, not significant, ****P < 0.0001.
- 17 January 2026
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 135, 118571
Discovery of the thieno[2,3-b][1,4]thiazin-2(3H)-one STING inhibitors
- 17 January 2026
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 135, 118571
Discovery of the thieno[2,3-b][1,4]thiazin-2(3H)-one STING inhibitors
- 11 December 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5271-5283
Discovery of isoindoline-2(1H)-carboxamide STING inhibitors as anti-inflammatory agents
STING (stimulator of interferon genes) is an endoplasmic reticulum-resident membrane-spanning protein that is widely expressed in mammalian cells and functions as a central regulator for the innate immunity. Aberrant activation of the STING axis due to loss-of-function or gain-of-function mutation leads to various autoimmune and autoinflammatory disorders such as Aicardi-Goutières syndrome, systemic lupus erythematosus, and STING-associated vasculopathy with onset in infancy. Here we report the design, synthesis, and structure–activity relationship (SAR) of the isoindoline-2(1H)-carboxamide STING inhibitors. SAR study allowed us to identify compound 3b as a potent STING inhibitor with human- and mouse-STING inhibitory IC50 values of 6.2 and 12.5 nM, respectively. It also markedly suppressed the activation of the STING pathway in both human and murine cells. Furthermore, compound 3b exhibited preferable in vivo protective efficacy against cisplatin-induced acute kidney injury. Graphical abstract
- 11 December 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (4) , 5271-5283
Discovery of isoindoline-2(1H)-carboxamide STING inhibitors as anti-inflammatory agents
STING (stimulator of interferon genes) is an endoplasmic reticulum-resident membrane-spanning protein that is widely expressed in mammalian cells and functions as a central regulator for the innate immunity. Aberrant activation of the STING axis due to loss-of-function or gain-of-function mutation leads to various autoimmune and autoinflammatory disorders such as Aicardi-Goutières syndrome, systemic lupus erythematosus, and STING-associated vasculopathy with onset in infancy. Here we report the design, synthesis, and structure–activity relationship (SAR) of the isoindoline-2(1H)-carboxamide STING inhibitors. SAR study allowed us to identify compound 3b as a potent STING inhibitor with human- and mouse-STING inhibitory IC50 values of 6.2 and 12.5 nM, respectively. It also markedly suppressed the activation of the STING pathway in both human and murine cells. Furthermore, compound 3b exhibited preferable in vivo protective efficacy against cisplatin-induced acute kidney injury. Graphical abstract
- 9 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 301, 118232
Discovery of a potent and orally bioavailable 3,3-dimethyl-2-oxoindoline STING inhibitor
- 9 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 301, 118232
Discovery of a potent and orally bioavailable 3,3-dimethyl-2-oxoindoline STING inhibitor